1. 23andMe and GSK in joint effort to mine customer DNA data with an eye to drug development — Biogen earnings — Speculation on JNJ opioid settlement total — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Whoa who’s running Market Access?

Discussion in 'Radius Health' started by anonymous, Jun 13, 2019 at 9:25 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Now here’s a team that’s falling apart! Every time I’m in the office it’s the same individuals back there. Where is everyone else? You’ve got remote folks building furniture and playing farmer in the dell, and traveling on the company’s money. Sorry guys don’t go boasting about it to others. Word travels. We’re paying these guys to do what? What an embarrassment. Hopefully the new VP cleans house. I’m not in the office much but I know for sure there are folks on this team who are taking advantage of no one watching. Makes me ill.
     

  2. anonymous

    anonymous Guest

    Who is the new VP?
     
  3. anonymous

    anonymous Guest

    You think that is unique,and only happens in market access. It is rampant throughout the organization. Ask JH where he has been with corporate monies. The salesforce is not the most productive group either. Why should they when all mistruths and lies have been told to them. There is no trust. or vision, they are not even lying about it. Enjoy the summer who knows what fall will bring.
     
  4. anonymous

    anonymous Guest

    Is insurance coverage still a problem?
     
  5. anonymous

    anonymous Guest

    It depends on your geography. Some places good others not. The bigger problem is cost and daily injection which leads a huge compliance issue for patients. The company has not yet dealt with this issue. The cost is related to medicare patients, which as you mostly likely know is not just a problem for Radius.

    However with that in mind Amgen has dealt with cost in a most effective way possible for their patients.
     
  6. anonymous

    anonymous Guest

    No new market access leadership yet?
     
  7. anonymous

    anonymous Guest

    There is no leadership anywhere...why should market access be any different
     
  8. anonymous

    anonymous Guest

    There are a few good folks remaining who are looking for opportunities before Radius folds. The true talent for the most part has moved on.
     
  9. anonymous

    anonymous Guest

    Name one good talent left in management .....
     
  10. anonymous

    anonymous Guest

    zero talent remaining
     
  11. anonymous

    anonymous Guest

    Could not agree more. Regional directors are a joke. First time they have had this position or they were let go by other companies, they may call it down-sizing but we know the difference. Add that to the fact there is no one to mentor or add guidance We all could all many stories about field rides and either micro management or a check box. Nothing is offered that is of any business development strategy, in my personal experience I just get how wonderful and successful they are or and what a good relationship they with KOL. Counting the days till the end.
     
  12. anonymous

    anonymous Guest


    Amgen drug is an expensive way to die
     
  13. anonymous

    anonymous Guest

    That comment is absurd. The cost of other drugs for diseases other then osteoporosis is ridiculous higher, Just lookout the cost of insulin, cancer and coronary artery disease, all of these lifetime medication. If you are speaking about the initial data, all redone, really can not make informed statement against. Amgen is a very successful company with resources that do not compare to ours, along with talented, committed individuals. Radius made early mistakes and refused to engage and listen to anyone until the profits lagged, sometimes you need a leader at the top who has his eye on the work force not just profit.